Verastem Inc

Despite the Stage 2 advancing structure and overall bullish trend, the Bullish Exhaustion pattern and overbought conditions suggest a corrective pullback into the 9/20-day EMA confluence around $7.32–$7.38. Medium-term bias remains bullish, but short-term execution is deferred until we see clear acceptance and momentum reacceleration from this support zone. A decisive move above recent highs near $7.66 would validate a fresh leg higher, while a break below support risks a deeper test of the 50-day SMA.

• ↑Q2 net product revenue $25.1M; FY revenue $30.9M indicates strong sales execution
• ↑13F institutional ownership remains high, signaling investor confidence
• ↓Negative profitability factors and earnings yield pressure indicate unsustainable margins